New targeted drug shows promise for BRAF-Mutant cancers in early trial
NCT ID NCT05668585
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tested a new drug called CFT1946, alone or with other drugs, in 89 adults with solid tumors that have a BRAF V600 mutation, including melanoma, lung, colon, and thyroid cancers. The main goals were to check safety and find the best dose. The study is complete, but results are not yet public.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- CFT1946 (a targeted drug), trametinib, and cetuximab
- What this could lead to
- If successful, this could point toward a new treatment option for people with certain hard-to-treat cancers that have a BRAF V600 mutation.
- What could go wrong
- This is an early phase 1/2 trial with only 89 participants, so results are preliminary. The drug may not work as hoped or could have serious side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANAPLASTIC THYROID CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Allina Health System DBA Virginia Piper Cancer Institute
Minneapolis, Minnesota, 55407, United States
-
Beatson West of Scotland Cancer Centre
Glasgow, G12 0YN, United Kingdom
-
Centre Leon Berard
Lyon, 69008, France
-
Chu de Lille
Lille, 59037, France
-
Community Health Network
Indianapolis, Indiana, 46250, United States
-
Complejo Hospitalario de Jaen
Jaén, 23007, Spain
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center
New York, New York, 10021, United States
-
Florida Cancer Specialists
Sarasota, Florida, 34232, United States
-
Hospital Clinico Universitario de Valencia
Valencia, 46010, Spain
-
Hospital General Universitario Gregorio Maranon
Madrid, 28007, Spain
-
Hospital Universitario 12 de Octubre
Madrid, 28041, Spain
-
Hospital Universitario Vall d'Hebron
Barcelona, 08035, Spain
-
IUCT Oncopole
Toulouse, 31059, France
-
Institut Bergonie
Bordeaux, 33076, France
-
KEM | Evang. Kliniken Essen-Mitte gGmbH
Essen, 45136, Germany
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
NEXT Oncology Barcelona
Barcelona, 08023, Spain
-
Sarah Cannon and HCA Research Institute
Nashville, Tennessee, 37203, United States
-
South Texas Accelerated Research Therapeutics (START) Madrid - Hospital Fundacion Jiminez Diaz
Madrid, 28040, Spain
-
The Christie NHS Foundation Trust
Manchester, M20 4BX, United Kingdom
-
Universitaetsklinikum Essen
Essen, 45147, Germany
-
University of Arizona - Cancer Center
Tucson, Arizona, 85719, United States
-
University of Wisconsin
Madison, Wisconsin, 53792, United States
-
Virginia Cancer Specialists (NEXT Oncology Virginia)
Fairfax, Virginia, 22031, United States
-
Washington University School of Medicine
St Louis, Missouri, 63110, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Dual-Pronged antibody outsmart advanced solid tumors?
- Can a new infusion drug shrink Hard-to-Treat tumors?
- Can new drug cocktails reawaken the immune system against melanoma?
- Can a pill keep lung cancer from returning after surgery?
- Could a Six-Month exercise and diet plan shield muscle during melanoma treatment?
- Quitting before the knife: which Stop-Smoking aid works best for cancer patients?